Acurx Pharmaceuticals, Inc.
ACXP
$3.10
$0.3211.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.17% | -1.81% | -24.01% | -45.08% | -37.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.12% | -28.23% | -44.94% | -50.91% | -45.38% |
| Operating Income | 42.12% | 28.23% | 44.94% | 50.91% | 45.38% |
| Income Before Tax | 43.26% | 29.37% | 45.50% | 50.91% | 45.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.26% | 29.37% | 45.50% | 50.91% | 45.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.26% | 29.37% | 45.50% | 50.91% | 45.61% |
| EBIT | 42.12% | 28.23% | 44.94% | 50.91% | 45.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 77.85% | 64.46% | 63.77% | 62.10% | 55.54% |
| Normalized Basic EPS | 77.85% | 64.46% | 63.77% | 62.09% | 55.54% |
| EPS Diluted | 77.85% | 64.46% | 63.77% | 62.10% | 55.54% |
| Normalized Diluted EPS | 77.85% | 64.46% | 63.77% | 62.09% | 55.54% |
| Average Basic Shares Outstanding | 156.16% | 98.70% | 50.44% | 29.51% | 22.33% |
| Average Diluted Shares Outstanding | 156.16% | 98.70% | 50.44% | 29.51% | 22.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |